Good DREAMM-1 Data Keeps GSK On Track For Multiple Myeloma Filing This Year

 
• By Sten Stovall

Confirmation of good trial data for GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 in multiple myeloma patients keeps it in the running for eventual regulatory approval by 2020 - but it faces a formidable field of emerging rival therapies.  

Stethoscope
GSK Hopes '916 will reach the MM market by 2020 • Source: Shutterstock

More from Clinical Trials

More from R&D